Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor (Monitor-GCSF)
International, Prospective, Open-label, Multicenter, Pharmacoepidemiological Study to Determine Predictors of Clinical Outcomes in Chemotherapy-treated Cancer Patients at Risk for Febrile Neutropenia and Treated Prophylactically With Filgrastim Biosimilar.
Sponsor: Sandoz
This observational or N/A phase trial investigates B-cell Lymphoma and Bladder Cancer and is currently completed. Sandoz leads this study, which shows 10 recorded versions since 2010 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed
-
Sep 2020 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Sep 2020 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Mar 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sandoz
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Agen, France , Alicante, Spain , Arras, France , Avezzano, Italy , Avignon, France , Avola, Italy , Barcelona, Spain , Bari, Italy , Bayonne, France , Beauvais, France and 106 more locations